Parkinson's Disease Trial, Not Yet Recruiting NCT07544953 Sponsor: Yonsei University Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Not Yet Recruiting

NCT07544953
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with Parkinson's disease
  • People whose brain scans (a specific type of PET scan) have confirmed a buildup of a protein called amyloid in the brain
  • People who have mild memory or thinking difficulties, based on neuropsychological testing (scored at CDR 0.5 or 1, which indicates mild cognitive impairment or early dementia)
  • Adults between the ages of 50 and 90 years

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People for whom the study drug, lecanemab, would be considered unsafe or unsuitable based on guidelines from the Korean Dementia Association
  • People whose brain condition is suspected to be caused by something other than Parkinson's disease or Alzheimer's disease

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 18 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 82-2-2228-1608

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
1 June 2030

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Changes in amyloid dposition on amyloid imaging scans

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 18 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov